Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is considered to be a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly. NSCLC can be categorized into three types, namely squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. SCLC constitutes roughly 10%-15% of all diagnosed cases of lung cancer. SCLC is categorized into two types, namely small cell carcinoma, and combined small cell carcinoma. It can be further classified into two stages, namely limited-stage SCLC and extensive-stage SCLC. Some of the common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Both SCLC and NSCLC are recurrent in nature and difficult to cure.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Economic burden

Types of lung cancer

Diagnosis

Staging of SCLC

Staging of NSCLC

Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape

Global lung cancer therapeutics market

Five forces analysis

PART 08: Market segmentation by disease type

NSCLC

Global NSCLC market overview

SCLC

Global SCLC market overview

PART 09: Market segmentation by type of molecule

Small molecules

Biologics

PART 10: Geographical segmentation

Lung cancer therapeutics market in Americas

Lung cancer therapeutics market in EMEA

Lung cancer therapeutics market in APAC

PART 11: Market drivers

Growing demand for targeted therapies

Presence of blockbuster drugs coupled with longer

patent exclusivities

Advancements in identification of molecular biomarkers

increasing patient pool

Paradigm shifts toward the adoption of checkpoint

inhibitors

PART 12: Impact of drivers

PART 13: Market challenges

Growing popularity of alternative therapeutics

High costs leading to low adoption rate

Adverse effects of drugs

PART 14: Impact of drivers and challenges

PART 15: Market trends

Emergence of nanomedicine platform for the treatment of

lung cancer

Advent of miRNA therapeutics in the treatment of lung

cancer

Growing strategic alliances for late-stage pipeline

Growing approvals in lung cancer therapeutics market

PART 16: Vendor landscape

Competitive scenario

PART 17: Key vendor analysis

F. Hoffmann-La Roche

Eli Lilly

AstraZeneca

Pfizer

Celgene

Other prominent vendors

PART 18: Appendix

List of abbreviations

PART 19: Explore Technavio